GHRP-6 vs Triptorelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
GHRP-6
GHRP-6 is a first-generation synthetic hexapeptide GH secretagogue that strongly stimulates pituitary GH release via ghrelin receptor activation. It is one of the oldest and most well-studied GHRPs, with a large body of research spanning more than three decades. GHRP-6 produces significant GH pulses but is notable for powerfully stimulating appetite — a side effect that can be beneficial for those in a caloric deficit or disadvantageous for those managing body composition.
Full profileTriptorelin
Potent synthetic GnRH agonist approximately 100× more potent than native GnRH. Used clinically for prostate cancer, endometriosis, and precocious puberty via sustained suppression. A single low dose (100mcg IM) is studied as a 'PCT restart' strategy that exploits the initial LH/FSH flare before receptor desensitization sets in.
Full profile| GHRP-6 | Triptorelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | Growth Hormone Releasing Peptide-6, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 | GnRH agonist, Decapeptyl, Trelstar, D-Trp6-LHRH |
| Evidence | Preclinical only | Research-stage |
| Dosing range | 100mcg–300mcg mcg, 1–3 times daily, on an empty stomach | 50mcg–200mcg mcg, Single-dose for PCT restart; every 2–4 weeks for sustained suppression (clinical) |
| Administration | Subcutaneous injection, Intramuscular injection | Intramuscular injection, Subcutaneous injection |
| Key side effects | Strong increase in appetite (most common and notable), Elevated cortisol and prolactin at higher doses, Water retention / bloating, Fatigue at high doses | Initial testosterone surge followed by suppression (with repeated dosing), Hot flashes, Decreased libido, Bone density loss (long-term repeated dosing) |
| Cited sources | 3 references | 2 references |
Key differences
- Evidence level differs: GHRP-6 is preclinical only, while Triptorelin is research-stage.
- Administration: GHRP-6 — Subcutaneous injection, Intramuscular injection; Triptorelin — Intramuscular injection, Subcutaneous injection.
- Frequency: GHRP-6 is typically 1–3 times daily, on an empty stomach; Triptorelin is Single-dose for PCT restart; every 2–4 weeks for sustained suppression (clinical).
- Research depth: this profile cites 3 sources for GHRP-6 vs 2 for Triptorelin.
How each works
GHRP-6
Human studies confirm GHRP-6 robustly elevates GH within 15–30 minutes of injection, with effects diminishing toward baseline within 2–3 hours. Chronic use increases baseline IGF-1. Research also indicates mild stimulation of cortisol and prolactin, particularly at higher doses. Animal models have shown potential cardioprotective, hepatoprotective, and muscle-sparing effects, though human equivalents are not established.
Triptorelin
Triptorelin produces a biphasic response: an initial agonist surge of LH and FSH (the 'flare effect') followed by complete pituitary desensitization with continued use. The single-dose PCT protocol leverages only the initial flare to jumpstart testosterone production. Clinical data supports LH surges of 10–20× baseline within hours of the first dose.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.